

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



撥康視云™

Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

INSIDE INFORMATION ANNOUNCEMENT UPDATE IN RELATION TO SETTLEMENT OF PROCEEDINGS

This announcement is made by Cloudbreak Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 7 January 2026 and 15 January 2026, respectively (collectively, the “**Announcements**”), in relation to, among other things, the Proceedings and the Settlement. Unless otherwise defined herein, capitalised terms have the same meanings as those given in the Announcements.

WITHDRAWAL OF ARBITRATION PROCEEDINGS

As disclosed in the announcement of the Company dated 15 January 2026, the Company, Cloudbreak Guangzhou and Cedar Wealth, among others, have entered into the Settlement Agreement, pursuant to which Cedar Wealth shall, in consideration of the payment by or on behalf of the Company of the Settlement Sum, forthwith upon receipt of such payment submit applications for the lifting of the Asset Preservation Order and the withdrawal of the Arbitration Proceedings, respectively.

The Board is pleased to announce that, on 28 January 2026, the Company and Cloudbreak Guangzhou received a copy of the notice of decision dated 23 January 2026 (the “**Notice of Decision**”) issued by the Shanwei Arbitration Commission* (汕尾仲裁委員會) (the “**Arbitration Commission**”) in relation to the application of Cedar Wealth for the withdrawal of the Arbitration Proceedings (the “**Withdrawal Application**”). Pursuant to the Notice of Decision, the Arbitration Commission has approved and granted the Withdrawal Application, and the arbitration fees in respect of the Arbitration Proceedings shall be borne by Cedar Wealth.

Further announcement(s) will be made by the Company to keep its shareholders and potential investors informed of the latest developments in relation to the Proceedings and the Settlement as and when appropriate and in compliance with the Listing Rules and the Inside Information Provisions.

Shareholders and potential investors of the Company should exercise caution and due care when dealing in the securities of the Company.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI Jinsong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 29 January 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive directors.

* *For identification purpose only*